ArticleFrontiers in bioengineering and biotechnology2021
Janus Magnetic Nanoplatform for Magnetically Targeted and Protein/Hyperthermia Combination Therapies of Breast Cancer.
Article in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Polymer-Based and Biomaterial Encapsulation of Probiotics for Improved Viability.Probiotics and antimicrobial proteins · 2026Review
- JAK/STAT3 axis in breast cancer: opportunities for intervention with natural phytochemical-based nanotherapeutics.Medical oncology (Northwood, London, England) · 2026Review
- Genesis, Health Benefits, and Future Perspectives of Probiotics: Exploring Endogenous and Exogenous Classes, Innovations, and Research Gaps.Probiotics and antimicrobial proteins · 2026Review
- First Report on Biosynthesis of Riboflavin by Microbacterium proteolyticum BWBTDIPO1 - Extraction, Characterization and Mechanistic Insight Via In-Silico Approach.Current microbiology · 2025Article
- Formulations of novel microbial medium from beetroot powder: a sustainable substitute for commercial Man-de-Rogosa Sharp agar (MRS) in cultivating lactic acid bacteria.World journal of microbiology & biotechnology · 2025Article
- Recent advancements and clinical aspects of engineered iron oxide nanoplatforms for magnetic hyperthermia-induced cancer therapy.Materials today. Bio · 2024Review
- Multidisciplinary advances in kombucha fermentation, health efficacy, and market evolution.Archives of microbiology · 2024Review
- PMTPred: machine-learning-based prediction of protein methyltransferases using the composition of k-spaced amino acid pairs.Molecular diversity · 2024Article
- Interferon Gamma Response in Human Saliva Following Exposure to the Oral Probiotic Streptococcus salivarius BLIS K12.Probiotics and antimicrobial proteins · 2024Article
- Treatment of type 2 diabetes mellitus with stem cells and antidiabetic drugs: a dualistic and future-focused approach.Human cell · 2024Review
- Advances in magnetic induction hyperthermia.Frontiers in bioengineering and biotechnology · 2024Review
- Alternative viewpoint against diabetic wound based on stem cell secretome that can mediated angiogenesis and reduce inflammation.Archives of dermatological research · 2023Article
- Evaluation of probiotics in vegetable juices: tomato (Solanum lycopersicum), carrot (Daucus carota subsp. sativus) and beetroot juice (Beta vulgaris).Archives of microbiology · 2022Article
- Nano-drug delivery system for pancreatic cancer: A visualization and bibliometric analysis.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein therapeutics have been considered a promising strategy for cancer treatment due to their highly specific bioactivity and few side effects. Unfortunately, the low physiological stability and poor membrane permeability of most protein drugs greatly limit their clinical application. Furthermore, single-modality protein therapeutics show insufficient efficacy. To address these issues, Janus magnetic mesoporous silica nanoparticles (Janus MSNNPs) were developed to preload ribonuclease A (RNaseA) to simultaneously realize the magnetically enhanced delivery of protein drugs and magnetic hyperthermia-enhanced protein therapy. Janus MSNNPs showed a high RNaseA loading ability and pH-responsive drug release behavior. Furthermore, an external magnetic field could remarkably enhance the therapeutic effect of RNaseA-loaded Janus MSNNPs due to the improved intracellular internalization of RNaseA. Importantly, Janus MSNNPs possessed an outstanding magnetic hyperthermia conversion efficiency, which could generate hyperthermia under an alternating magnetic field, effectively supplementing protein therapy by a combined effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.